Related Experiment Video
Updated: Oct 17, 2025
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
13.8K
Renal tumor biomarkers (Review)
Ovidiu Bratu1,2,3, Dan Mischianu1,2,3, Dragos Marcu1,2
1Department of Urology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Experimental and Therapeutic Medicine
|October 11, 2021
Summary
Identifying novel molecular markers for renal cell carcinoma (RCC) is crucial for early detection and improved patient outcomes. This review explores promising biomarkers for prognosis, treatment, and follow-up in RCC management.
Area of Science:
- Oncology
- Biomarker Discovery
- Molecular Diagnostics
Background:
- Renal cell carcinoma (RCC) is a prevalent cancer, particularly in developed nations, affecting individuals aged 60-70.
- Early detection of RCC significantly reduces morbidity, highlighting the need for sensitive diagnostic tools.
- Molecular markers in blood and urine offer potential for early RCC detection, diagnosis, and post-treatment monitoring.
Purpose of the Study:
- To review and identify the most valuable tumor markers for clinical application in renal tumors.
- To assess the potential of gene and protein expression analysis for discovering new RCC biomarkers.
- To explore the role of biological markers in predicting metastatic potential and guiding patient treatment.
Main Methods:
- Literature review of existing studies on renal cell carcinoma biomarkers.
- Analysis of gene and protein expression patterns associated with RCC.
- Investigation of tumor cell biological features linked to metastatic potential.
Main Results:
- Molecular markers show promise for early RCC detection, diagnosis, and follow-up.
- Gene and protein expression analyses are key areas for new biomarker development.
- Tumor cell phenotype transformation is linked to RCC metastatic potential, suggesting markers for prognosis.
Conclusions:
- Validated molecular markers are needed for effective clinical management of RCC.
- Further investigation into tumor markers is essential for improving patient prognosis and treatment strategies.
- Biomarkers hold significant potential for personalized treatment and follow-up in renal tumors.
